webinar register page

SynBioBeta COVID-19 Town Hall with JCVI's Richard Scheuermann on coronavirus immune epitopes
(J. Craig Venter was scheduled to join tomorrow's SynBioBeta Town Hall. In response to intense interest about JCVI's research on SARS-CoV-2 immune epitopes, Craig has asked the leader of this work, Richard Scheuermann, to be our guest in tomorrow's discussion. Craig will join us for a broader discussion about the state of the synthetic biology industry in the coming weeks.)

There’s limited information about which parts of the SARS-CoV-2 virus elicit a strong immune response, which is extremely relevant in the design of promising vaccine candidates. Richard Scheuermann, Director of JCVI’s La Jolla facility, and his collaborators recently published a first analysis of the most promising epitope targets, based on analysis of SARS-CoV (2003) and the novel SARS-CoV-2 (2019). Richard will describe the findings, and also discuss:

- Some background on coronavirus features and its evolution
- Computational approaches in support of vaccine development
- B-cell versus T-cell strategies for fighting COVID-19
- How we can develop more effective vaccines using conserved epitope strategies

Mar 31, 2020 08:00 AM in Pacific Time (US and Canada)

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: SynBioBeta.